Royalty Pharma has eased one of its conditions for completing its recently increased offer to buy Irish drugmaker Elan Corp. PLC for $12.50 per share, or about $7.5 billion. The New York company said Thursday it had lowered a threshold for the percentage of shareholders who must vote for the deal to more than 50 percent from 90 percent.
Royalty Pharma has eased one of its conditions for completing its recently increased offer to...
Irish drugmaker Elan plans to pay $1 billion for the right to future royalties...
Royalty Pharma has raised its offer to buy Elan on the condition that shareholders reject the Irish drugmaker's push to refocus its business through a string of recently announced deals, including two new deals unveiled Monday. Royalty said Monday it will pay $12.50 in cash for each share of Elan Corp. PLC. That adds up to a total value of about $7.5 billion.
Xellia Pharmaceuticals, a pharmaceutical group focusing on the development, manufacturing and global commercialization of anti-infective therapies, announced today that Novo A/S, the holding company of the Novo Group, has purchased all shares of the group for approximately US$ 700 million from 3i and other current shareholders.
Actavis is buying Warner Chilcott in an all-stock transaction valued at about $8.5 billion which would create the third-biggest specialty pharmaceutical company in the U.S. The announcement on comes after the two companies said earlier this month that they were in talks about a possible combination.
Frazier Healthcare and Packaging Coordinators, Inc. today announced that they have completed the acquisition of pharmaceutical packager AndersonBrecon from its parent company AmerisourceBergen Corporation. AndersonBrecon will now merge with and operate as Packaging Coordinators, Inc.
The drugmakers Actavis Inc. and Warner Chilcott PLC say they are holding early discussions about a possible combination of the two companies. The companies say there is no guarantee that Actavis will make an offer for Warner Chilcott, however. Actavis expects to generate more than $8.1 billion...
Actavis Inc. said Wednesday it acquired a bacterial vaginosis gel developed by Valeant Pharmaceuticals International Inc. Actavis said it agreed to pay Valeant $55 million for its metronidazole gel product, which has not yet received marketing approval. The total includes both an upfront payment...
Bayer AG says it has agreed to buy California-based Conceptus for around $1.1 billion to expand the kinds of birth control it offers. Bayer said Monday it would launch a public offer to pay $31.00 per share for all the stock in Conceptus, Inc., which is based in Mountain View.
OPKO Health, Inc. and PROLOR Biotech, Inc. announced that the companies have signed a definitive merger agreement under which OPKO will acquire PROLOR, a biopharmaceutical company focused on developing and commercializing longer-acting proprietary versions of already approved therapeutic proteins.
LifeMap Sciences, Inc., a subsidiary of BioTime, Inc., announced a collaborative partnership and value-added reseller agreement with Appistry, Inc., which provides big-data computing that supports life-science and medical analytics at hospitals and medical research centers and organizations.
Miltenyi Biotec has completed acquisition of Owl biomedical, Inc., an emerging company developing and commercializing microchip-based cell sorting systems using fully-closed disposable cartridges in an easy-to-use format. The acquisition underscores Miltenyi’s commitment to bringing comprehensive solutions to the research and clinical cell therapy markets.
The board of Irish drugmaker Elan has unanimously rejected a takeover bid from Royalty Pharma, saying the U.S. investment company's offer of $11.25 a share is much too low. Royalty last week lowered its bid for Elan from an original $12 per share offer, pricing in the result of a $1 billion share...
Entegris, Inc., a supplier of contamination control and materials handling solutions for very demanding manufacturing environments, today reported it acquired the assets of privately held Jetalon Solutions, Inc., a California-based supplier of fluid metrology products.
Royalty Pharma is raising its bid for Irish drugmaker Elan Corp. PLC to as much as $12 per share, or $7.2 billion. Royalty Pharma, a private company based in New York, offered in February to buy the company for $11 per share, or about $6.5 billion. Elan rejected that bid.
Upon completion of the merger BioSante will issue to ANI stockholders shares of BioSante common stock such that the former ANI stockholders will own 57 percent of the combined company’s shares of common stock outstanding, and the former BioSante stockholders will own 43 percent. In a change from the prior merger agreement, these ownership percentages will not be subject to adjustment.
Thermo Fisher Scientific and Life Technologies Corporation have signed a definitive agreement under which Thermo Fisher will acquire Life Technologies for $76.00 in cash per fully diluted common share, or approximately $13.6 billion, plus the assumption of net debt at close ($2.2 billion as of year end 2012).
German drugmaker Merz Pharma Group has ended a plan to acquire Obagi Medical Products Inc. after a competitor raised its bid to buy the dermatology products maker. Merz said Monday it is a "disciplined buyer," and it was withdrawing its $22-per-share cash bid for Obagi after Canadian drugmaker Valeant Pharmaceuticals raised its offer last week to $24 per share.
Valeant Pharmaceuticals International, Inc. today announced that Valeant and Obagi Medical Products, Inc. have executed an amendment to their Agreement and Plan of Merger, dated March 19, 2013. Pursuant to the amendment, Valeant increased its offer to acquire Obagi from $19.75 to $24.00 per share in cash.
AstraZeneca today announced that MedImmune, its global biologics research and development unit, has acquired AlphaCore Pharma, an Ann Arbor, Michigan-based biotechnology company focused on the development of ACP-501, a recombinant human lecithin-cholesterol acyltransferase (LCAT) enzyme.
German drugmaker Merz Pharma Group said Tuesday that it wants to buy dermatology products maker Obagi for about $383.5 million, toping an offer made by Canada's Valeant Pharmaceuticals last month. Merz said it sent a letter to Obagi Medical Products Inc.'s board offering to buy all of the company's stock for $22 per share.
Biogen Idec has completed its purchase of Elan Corporation’s interest in TYSABRI ® (natalizumab) and has gained full strategic, commercial and decision-making rights to TYSABRI. The transaction was originally announced on February 6, 2013.
AmerisourceBergen Corporation today announced that it has signed a definitive agreement to sell its contract packaging business, AndersonBrecon, to an entity formed by affiliates of an investor group led by Frazier Healthcare VI, L.P. for the purpose of acquiring AndersonBrecon.
AmerisourceBergen Corporation today announced that it has signed a definitive agreement to sell its Canadian pharmaceutical distribution business, AmerisourceBergen Canada Corporation (ABCC), to Kohl & Frisch Limited, a Canadian-owned national full-line distributor. The transaction is expected to close in the third quarter of fiscal 2013.
Baxter International Inc. has closed its acquisition of a potential hemophilia treatment from the French drugmaker Ipsen and Inspiration Biopharmaceuticals Inc. in a deal that could be worth more than $180 million. Baxter had said in January it agreed to buy the drug, labeled OBI-1, and related manufacturing operations.
Cerecor, a development-stage biotechnology company, said Wednesday it agreed to acquire potential treatments for Parkinson's disease and other central nervous system disorders from Merck & Co. Cerecor Inc. of Baltimore said it is gaining the worldwide rights to develop and market drugs called...
BioClinica ®, Inc., a global provider of clinical trial management services, announced today that JLL Partners and Ampersand Capital Partners, two leading middle market private equity firms, have completed their acquisition of BioClinica and CoreLab Partners and have combined the two companies under the name BioClinica.